Shots:
- The NMPA has approved telitacicept for the treatment of AChR antibody-positive gMG in combination with standard therapies
- In P-III trial for gMG, telitacicept demonstrated favorable efficacy vs PBO, with 98.1% vs 12% pts achieving ≥3-point MG-ADL reduction (-5.74 vs -0.91) as well as 87% vs 16% pts having ≥5-point QMG reduction (-8.66 vs -2.27) at 24wks., as presented at AAN 2025
- Telitacicept, a novel fusion protein that inhibits BLyS & APRIL for the treatment of autoimmune diseases, will advance into a global P-III trial for the treatment of myasthenia gravis
Ref: Prnewswire| Image: Remegen| Press Release
Related News:- Remegen Reports P-III Trial Data of Telitacicept for Generalized Myasthenia Gravis (gMG)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
